ICER Report Drops Biogen’s Aduhelm $56k Price Tag by 95%, Notes Potentially Serious Side Effects

The Institute for Clinical and Economic Review (ICER) has published a revised report on Alzheimer’s disease drug Aduhelm. Although Biogen prices the drug at $56,000 per year, ICER found that the cost should be substantially lower—between $3,000 and $8,400 per year.

“ICER feels that the evidence for Aduhelm is ‘insufficient’ to prove the drug has a net health benefit for patients with mild cognitive impairment due to Alzheimer’s disease, as well as patients with mild Alzheimer’s disease. The watchdog added that evidence suggests Aduhelm’s side effects are common and ‘potentially serious’, with the two phase 3 trials of the drug producing ‘contradictory’ results as to whether it can slow the progression of the disease or improve cognition.” Read more here.

(Source: Lucy Parsons, PMLiVE, 7/1/21)